Studie KRT-232-101 Part B

KRT-232-101 Part B

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

NCT03662126

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

Zielgerichtet